These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 16623815

  • 1. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K, Davidson BR, Patch DW, Burroughs AK.
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [Abstract] [Full Text] [Related]

  • 2. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 3. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J.
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [Abstract] [Full Text] [Related]

  • 4. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 5. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 6. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [Abstract] [Full Text] [Related]

  • 7. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J.
    Transplantation; 2003 Apr 15; 75(7):1020-5. PubMed ID: 12698091
    [Abstract] [Full Text] [Related]

  • 8. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients.
    Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L.
    Liver Transpl; 2004 Mar 15; 10(3):404-7. PubMed ID: 15004768
    [Abstract] [Full Text] [Related]

  • 9. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.
    Liver Transpl; 2004 Oct 15; 10(10):1258-62. PubMed ID: 15376310
    [Abstract] [Full Text] [Related]

  • 10. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
    Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A.
    Liver Transpl Surg; 1999 Jul 15; 5(4):294-300. PubMed ID: 10388502
    [Abstract] [Full Text] [Related]

  • 11. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.
    Manousou P, Cholongitas E, Samonakis D, Tsochatzis E, Corbani A, Dhillon AP, Davidson J, Rodríguez-Perálvarez M, Patch D, O'Beirne J, Thorburn D, Luong T, Rolles K, Davidson B, McCormick PA, Hayes P, Burroughs AK.
    Gut; 2014 Jun 15; 63(6):1005-13. PubMed ID: 24131637
    [Abstract] [Full Text] [Related]

  • 12. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A.
    Transpl Int; 2005 Dec 15; 18(12):1336-45. PubMed ID: 16297052
    [Abstract] [Full Text] [Related]

  • 13. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP, Ciccarelli O, Mauel E, Gheerardhyn R, Talpe S, Sempoux C, Laterre PF, Roggen FM, Van Leeuw V, Otte JB, Gianello P.
    Transpl Int; 2001 Dec 15; 14(6):420-8. PubMed ID: 11793040
    [Abstract] [Full Text] [Related]

  • 14. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May 15; 37(4):1700-2. PubMed ID: 15919436
    [Abstract] [Full Text] [Related]

  • 15. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct 15; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 16. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation.
    Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, Futagawa S.
    Surg Today; 2003 Oct 15; 33(6):421-5. PubMed ID: 12768367
    [Abstract] [Full Text] [Related]

  • 17. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome.
    Rodríguez-Perálvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, Rolando N, Dhillon AP, Patch D, O'Beirne J, Thorburn D, Burroughs AK.
    J Hepatol; 2013 Feb 15; 58(2):262-70. PubMed ID: 23023010
    [Abstract] [Full Text] [Related]

  • 18. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F.
    Transplantation; 2008 Dec 27; 86(12):1666-71. PubMed ID: 19104402
    [Abstract] [Full Text] [Related]

  • 19. European randomised trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients.
    Chang RW, Snowden S, Palmer A, Kwan JT, Nicholson M, Kashi SH, Fernando ON, Perner F, Neild GH.
    Transpl Int; 2001 Dec 27; 14(6):384-90. PubMed ID: 11793035
    [Abstract] [Full Text] [Related]

  • 20. Liver transplantation and hepatitis C virus. Results in a Spanish center since 1989.
    Loinaz C, Lumbreras C, Moreno E, Colina F, Fuertes A, Gómez R, Jiménez C, González-Pinto I, García I, Rojas J, Bellorín C.
    Hepatogastroenterology; 2001 Dec 27; 48(41):1435-42. PubMed ID: 11677981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.